IFNGR1 and neoplasm: Taking a novel pool-based screening approach in a murine B-ALL model, we observed that in vivo loss of IFNγR/JAK/STAT signaling and components of the antigen processing and presentation pathway, rendered tumor cells more sensitive to CAR-T therapy.